Clinical safety of peptide pulsed dendritic cell vaccine after radiofrequency ablation for hepatocellular carcinoma

Clinical safety of peptide pulsed dendritic cell vaccine after radiofrequency ablation for hepatocellular carcinoma - Clinical safety of peptide pulsed dendritic cell vaccine after radiofrequency ablation for hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020811

Enrollment

Registered

2016-01-31

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Peptide pulsed dendritic cell

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HLA-A24(+) patients with Hepatocellular carcionma

Exclusion criteria

Exclusion criteria: Immunodeficiency

Design outcomes

Primary

Measure	Time frame
Adverse event after vaccination	—

Secondary

Measure	Time frame
Immune monitoring	—

Countries

Japan

Contacts

Public ContactMasaaki Kitahara

Kanazawa University Hospital Department of Gastroenterology

mkitahara@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026